10-Q: SelectQuote Reports Second Quarter Results, Revenue Jumps 27% Year-Over-Year

SelectQuote's second quarter results show a significant revenue increase of 27% year-over-year, driven by growth in pharmacy and commission revenues.

Summary

• SelectQuote, Inc. reported a 27% increase in total revenue for the three months ended December 31, 2023, reaching $405.4 million, compared to $319.2 million in the same period of 2022.
• The company's pharmacy revenue saw a substantial increase of 111%, rising from $51.6 million to $108.8 million.
• Commission revenue also grew by 14%, from $230 million to $263.2 million.
• Net income for the quarter was $19.4 million, compared to $22.5 million in the prior year.
• For the six months ended December 31, 2023, total revenue increased by 32% to $638.2 million, compared to $481.7 million in the same period of 2022.
• The company reported a net loss of $11.7 million for the six months ended December 31, 2023, compared to a net loss of $20 million for the same period in 2022.
• The number of SelectRx members increased by 59% year-over-year, reaching 62,623 members as of December 31, 2023.
• The company's total submitted policies increased by 6% for the three months ended December 31, 2023, and 7% for the six months ended December 31, 2023.
• The lifetime value (LTV) per Medicare Advantage approved policy increased by 7% for the three months ended December 31, 2023, and 4% for the six months ended December 31, 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is strong, the decrease in net income and the potential need for a capital raise raise concerns. The company's expansion into healthcare services is a positive, but the overall financial performance is not yet fully stable.

Positives

• The company experienced strong revenue growth, driven by both pharmacy and commission revenues.
• SelectRx membership saw substantial growth, indicating increased adoption of their healthcare services.
• The LTV per Medicare Advantage approved policy increased, suggesting improved profitability per policy.
• The company's total submitted policies increased, indicating a growing customer base.

Negatives

• Net income decreased for the three months ended December 31, 2023, compared to the same period in 2022.
• The company reported a net loss for the six months ended December 31, 2023.
• Marketing and advertising expenses increased by 30% for the three months ended December 31, 2023, and 22% for the six months ended December 31, 2023.

Risks

• The company's reliance on a few major customers poses a concentration risk.
• The company's debt obligations and compliance with debt covenants could impact liquidity.
• The company's marketing and advertising expenses are increasing, which could impact profitability.
• The company is currently in a three-year cumulative loss position, which may impact the valuation of deferred tax assets.

Future Outlook

The company believes that the cash available under the Senior Secured Credit Facility will be sufficient to meet its projected operating and debt service requirements for at least the next 12 months. The company does not expect to generate sufficient cash flows from operations to enable it to repay all outstanding amounts under the Senior Secured Credit Facility at the time of its maturity on February 15, 2025.

Industry Context

The company's growth in pharmacy revenue reflects a broader trend of healthcare companies expanding into direct-to-consumer services. The increase in commission revenue is consistent with the ongoing demand for insurance products, particularly in the senior health market.

Comparison to Industry Standards

• SelectQuote's revenue growth of 27% year-over-year for the quarter is strong compared to industry averages for insurance brokers and healthcare service providers.
• The 111% increase in pharmacy revenue is significantly higher than the average growth rate for pharmacies, indicating a successful expansion of SelectRx.
• The company's LTV per Medicare Advantage approved policy is also above industry averages, suggesting a strong ability to generate long-term value from its customers.
• However, the company's net loss for the six months ended December 31, 2023, is a concern, as many of its competitors are profitable.

Legal Proceedings

• The company is subject to ongoing securities class action lawsuits and a stockholder derivative action, which could be costly to defend and divert management's attention.

Related Party Transactions

• SelectRx leases the Monaca facility from an Executive Vice President of SelectRx.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and potential need for a capital raise.
• Employees may be affected by any potential restructuring or reduction in operations.
• Customers may benefit from the company's expanded healthcare services.
• Suppliers and creditors may be impacted by the company's financial performance and debt obligations.

Next Steps

• The company will continue to monitor its financial performance and compliance with debt covenants.
• The company will explore options for refinancing or securing additional financing to address its debt obligations.
• The company will continue to focus on growing its pharmacy business and improving its customer acquisition strategies.

Key Dates

Keywords

SelectQuote, revenue, pharmacy, commissions, Medicare Advantage, insurance, SelectRx, healthcare services, financial results, LTV